The user started taking Finasteride 1mg daily on June 24, 2024, with no negative side effects and shares weekly progress pictures. They use coconut oil for deep conditioning weekly.
The user is considering starting dutasteride (DUT) 0.5mg for hair loss due to lack of access to finasteride and is concerned about potential side effects. They seek guidance on whether to begin this treatment.
The conversation humorously discusses diverting DHT from head to body hair and explores the idea of transplanting body hair to the scalp. It also mentions the potential for treatments to prevent DHT from affecting hair follicles.
A 22-year-old male is experiencing hair loss and has been using topical minoxidil and anti-dandruff shampoo for six months without improvement. Suggestions include adding finasteride to the routine and considering treatments for potential scalp issues like seborrheic dermatitis.
Finasteride and Dutasteride will remain accessible in the EU despite objections from France and Belgium. Users discuss the ease of obtaining these medications in different countries and express relief and support for the EU's decision.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
The user shared progress on hair restoration using dutasteride, oral minoxidil, and 2800 grafts, noting significant improvement in hair thickness and coverage. They discussed the importance of continuing DHT blockers like finasteride or dutasteride post-transplant to prevent further hair thinning.
A physician experienced hair thickening and new growth using microneedling and minoxidil, but stopped using topical finasteride due to side effects like reduced libido and erectile dysfunction. The physician plans to continue with microneedling and minoxidil, considering finasteride nonessential for cosmetic purposes.
The user is experiencing hair thinning and bald spots, using Nizoral, rosemary oil, fluocinolone, and receiving PRP treatments. They are considering oral minoxidil and finasteride but are hesitant due to age and financial constraints.
A 15-year-old is experiencing hair loss and is considering treatment options. They are aware they cannot use DHT blockers like finasteride due to their age and are exploring other causes like Telogen Effluvium.
The user reported significant improvement in hair quality and stability using topical finasteride for two years, without side effects. They later added minoxidil, which may have further enhanced hair quality.
The user is using a regimen of topical finasteride (.025% concentration), minoxidil, Nutrafol, and vitamin D to address hair loss. They experienced initial side effects but reported improvement over 11 weeks and are considering increasing the dosage.
The conversation discusses hair loss treatments, including Avodart (Dutasteride), finasteride, minoxidil, and peptide serums with ingredients like Redensyl and Saw Palmetto. Users share experiences and opinions on the effectiveness and side effects of these treatments, with some skepticism about claims regarding DHT and its role in hair loss.
A 26-year-old shares their experience with hair loss treatment using minoxidil and finasteride, noting improvements in hair thickness and health. Despite positive results, they experience mood swings and decreased libido, leading them to consider stopping the treatment.
The conversation is about using a topical spray containing minoxidil, finasteride, and tretinoin for hair regrowth over six months, with positive results and minimal side effects. The user also mentions using biotin and alpecin, and discusses the benefits of topical application over oral forms.
GT-20029 is discussed as a potential hair loss treatment, with concerns about its safety and systemic absorption compared to finasteride. Users express skepticism about its effectiveness and safety, noting that it may not surpass existing treatments like finasteride and minoxidil.
The user shared progress pictures showing significant hair regrowth from using finasteride, RU58841, and liquid minoxidil, emphasizing the importance of consistency. They noted that RU58841, a research chemical not FDA-approved, was effective when applied topically but warned of potential heart-related side effects.
Genetic variations influence how people respond to dutasteride for hair loss, with some benefiting more from finasteride. Dutasteride is effective for most, but genetic differences may cause it to be less effective for some.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
Way-316606 is considered a potential hair loss treatment but is avoided due to safety concerns and lack of research. Minoxidil and Finasteride are preferred as established treatments.
The user shares their hair growth progress using topical and sublingual minoxidil, dutasteride, hormone replacement therapy, and a laser comb. They report thicker hair and reduced hairline shedding, seeking advice for further thickening.
A 51-year-old woman switched from Minoxidil to Maneup, a copper peptide treatment, experiencing initial hair loss but later regrowth with different hair texture. Users debated Maneup's effectiveness, with some considering it alongside finasteride.
The user is experiencing sudden hair loss and is considering micro-needling, low-level light therapy, iron supplements, folihair, and Omega 3. They are hesitant to start finasteride, suspecting the hair loss might be due to telogen effluvium from a past COVID-19 infection.
A new hair growth spray in the UK contains finasteride 0.3%, minoxidil 5%, and tretinoin 0.01%, but some users find the finasteride concentration too high. Another brand offers a similar spray with a lower finasteride dose at a cheaper price, and some users report scalp irritation from the new spray.
DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.
A 19-year-old male started taking 1.2 mg finasteride and 3 mg minoxidil orally for hair thinning, noticing no shedding and some new baby hair but concerns about overall hair thinning. Users advised patience, suggesting thinning might be due to shedding, which is a normal part of the treatment process.
VDPHL-01 is essentially a slow-release oral minoxidil, which is already known to work for hair growth. The formulation includes other ingredients like Medrogestone, Valproic acid, Setipiprant, and Cetirizine, but their effectiveness and necessity are questioned.
GT20029 and pyrilutamide are both androgen antagonists but work differently; GT20029 degrades the androgen receptor, while pyrilutamide blocks DHT from binding. GT20029 is expected to have similar efficacy to CosmeRNA.
The user has been using finasteride for 10 months with no significant regrowth but no further hair loss and is considering adding oral minoxidil despite concerns about side effects. Other users suggest combining finasteride with minoxidil for better results, as finasteride prevents further hair loss while minoxidil aids regrowth.
Finasteride is favored for hair loss due to FDA approval, accessibility, and manageable side effects. Dutasteride, though more effective in reducing DHT, is used off-label and may have more side effects.